Biopharma AI
By
Can Eli Lilly’s Orforglipron Overtake Novo Nordisk’s Rybelsus in the Race for Oral GLP-1 Leadership?
Indianapolis, Ind., 2026 — Eli Lilly and Company today announced positive head-to-head Phase 3 results demonstrating that its…
Is Johnson & Johnson Preparing to Divest DePuy Synthes in a $20 Billion Strategic Pivot Toward Pharmaceuticals?
Will Johnson & Johnson’s Orthopedics Review Reshape the Global MedTech Landscape? Johnson & Johnson is reportedly exploring a…
Can Unnatural Products and Novartis Unlock “Undruggable” Cardiovascular Targets with AI-Designed Macrocyclic Peptides?
Santa Cruz, Calif., February, 2026 — Unnatural Products, Inc. (UNP) today announced a research collaboration and licensing agreement…
Can Foundation Medicine and Manifold Redefine Precision Oncology Through AI-Driven Genomic Analytics?
Are Foundation Medicine and Manifold Signaling the Next Evolution of AI-Integrated Oncology Intelligence? In a strategic move to…
China’s $2-3B AI Healthcare Pilots Launch: Rural Revolution or Data Control Play?
China’s National Health Commission launched pilots March 1-3, 2026, under its CNY 15-20B ($2-3B) AI strategy—rolling out AI…
NVIDIA Survey: 70% US Healthcare AI Adoption—Efficiency Lifeline or Insider Breach Timebomb?
NVIDIA’s March 1 survey shows 70% of US healthcare organizations now use AI, mainly to save time on…
